![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1339, 2002-01, pp. : 8-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Arya Arash Haghjoo Majid Sadr-Ameli Mohammad
Cardiovascular Drugs and Therapy, Vol. 19, Iss. 3, 2005-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Natalizumab in MS well tolerated
Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
NSAIDs increase CV risk in coronary artery disease
Reactions Weekly, Vol. 1, Iss. 1363, 2011-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Candesartan CREATEs promise in coronary artery disease
Inpharma, Vol. 1, Iss. 1614, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Celecoxib: beneficial effects in coronary artery disease
Inpharma, Vol. 1, Iss. 1374, 2003-01 ,pp. :